1. Introduction {#sec1}
===============

Isatins are a class of structurally versatile molecules and their core structure appears in many biologically active molecules and pharmaceutical agents. Isatin derivatives have been reported to possess a broad spectrum of activities such as anticancer \[[@bib1],[@bib2]\], antidepressant \[[@bib3]\], anticonvulsant \[[@bib4]\], antifungal \[[@bib5]\], anti-HIV \[[@bib6]\]and anti-inflammatory \[[@bib7]\], etc. In the last decade, N-substituted isatins have attracted increasing attention from both industry and academia. Vine et al. has reported that some N-benzyl isatin derivatives were more cytotoxic than their N-H counterparts toward some lymphoma cells as well as a series of human cancer cell lines, including human leukemic (K562, U937 and Jurkat), liver (HepG2), breast (MDA-MB-231 and MCF-7), prostate (PC-3) and colorectal (HCT-116) cell lines \[[@bib8]\]. Chen\'s and Chiyanzu\'s groups reported that N-substituted isatin derivatives exhibited inhibition activities against SARS CoV 3CLpro and parasitic cysteine proteases \[[@bib9],[@bib10]\]. Later on, Limpachayaporn and Liu found that 5-sulfonylisatin analogues could act as caspase-3,7 inhibitors and SARS-CoV 3C-like protease inhibitors \[[@bib11],[@bib12]\]. In addition, Chinnasamy\'s group found that some N-1 and C-5 disubstituted molecules such as 1-(substituted benzylidene)-3-(1-(morpholino/piperidinomethyl)-2,3-dioxoindolin-5-yl)urea derivatives exhibited antiepileptic activity and neurotoxicity \[[@bib13]\]. Previously, we reported some 5-(2-carboxyethenyl)isatin derivatives as anticancer agents, and found that the combination of a 5-\[trans-2-(methoxycarbonyl)ethen-1-yl\] group and a 1-(4-methoxybenzyl) group (compound **5--61**, [Fig. 1](#fig1){ref-type="fig"} ) in isatin significantly enhanced it\'s cytotoxic activity \[[@bib14]\]. However, further research on this molecule indicated that the presence of a metabolically unstable acrylic ester moiety on the C-5 position is the key to its in *vivo* efficacy. In order to further improve the antitumor property of this type of 1,5-disubstituted isatin molecules, we have synthesized a serious of isatin derivatives and studied their cytotoxicity. The results showed that although the substituent of 5-methacrylate could increase the antitumor activity of the target compound, it is not stable in metabolic processes (unpublished data). Therefore, we report a series of new compounds in this paper, which can maintain good anti-tumor efficacy even without the use of 5-methacrylate substituents. Among them, compound **2m** was shown as the most active compound against human leukemia K562 cells. Moreover, the molecular mechanism of the cytotoxic activity of compound **2m** was explored on anti-migration and anti-angiogenesis.Fig. 1The structure of 1,5-disubstituted isatin derivative (compound **5--61**).Fig. 1

2. Chemistry {#sec2}
============

Firstly, the target compounds were synthesized according to the procedures outlined in [Scheme 1](#sch1){ref-type="fig"} . Monosubstituted isatins **1a**-**1g** were obtained in two steps with a improved yield of 55--80% \[[@bib15]\]. Moreover, 5-Bromoisatin (**1d**) was coupled with six different boronic acids by microwave-assistant Suzuki coupling reaction to afford compounds **1h**-**1k** in 70--80% isolated yield \[[@bib16]\]. Secondly, N-alkylation of **1i** led to the synthesis of compounds **2a-2v** in good to excellent yield (75--90%). Thirdly, compound **3a-3c** were prepared from isatin derivatives by suzuki-coupling reaction ([Scheme 2](#sch2){ref-type="fig"} ). Finally, compound **4a-4s** were prepared from 5-bromo-1-(4-methoxybenzyl)indoline-2,3-dione by Suzuki-coupling ([Scheme 3](#sch3){ref-type="fig"} ).Scheme 1Synthesis of isatin derivatives (**1a**-**1k**, **2a**-**2v**).Scheme 1Scheme 2Synthesis of **3a**-**3c.**Scheme 2Scheme 3Synthesis of **4a**-**4r.**Scheme 3

Compounds **5a-5k** ([Scheme 4](#sch4){ref-type="fig"} ) were prepared from **2m** in good yield in one or two steps. Compound **2m** was reduced with NaBH~4~ in methanol under room temperature to afford compound **5a**. Compound **5b** was prepared by treatment of the compound **2m** with methylmagnesium bromide in tetrahydrofuran at −78 °C. Compound **2m** was reduced with hydrazine monohydrate in ethanol under reflux to afford compound **5c**. Compound **5d** and **5e** were prepared by treatment of the compound **2m** with (triphenylphosphoranylidene)acetate in tetrahydrofuran at room temperature. Compound **5f** was synthesized by treatment of the compound **2m** with ethylene glycol in toluene at 110 °C. Compound **5g** was prepared by treatment of the compound **2m** with diethylaminosulfur trifluoride in DCM at reflux. Compound **5h** was synthesized by treatment of the compound **2m** with hydroxylamine hydrochloride in ethanol at reflux. The compounds **5i-5k** were prepared by the treatment of **5c** with benzaldehyde or substituted benzaldehyde and pyridine in ethanol.Scheme 4C-3 modification of isatin derivatives (**5a-5k**).Scheme 4

The data obtained from ^1^H NMR, ^13^C NMR and Mass Spectrometry confirmed the proposed structures (Spectral data results are provided in supporting information).

3. Results and discussion {#sec3}
=========================

When contemplating a new class of 1,5-substituted isatin structure that could avoid the metabolically liabile acrylic acid ester group found in compound **5--61** while maintaining its biological potency, we envisaged a general structure compound **5--61** ([Fig. 1](#fig1){ref-type="fig"}) \[[@bib14]\]. It can bear a various of aromatic groups at the C-5 position, that carry some structural similarity in terms of their size and conjugation property, whereas the *in vivo* Michael addition liability of the 5-acrylic acid ester group could be eliminated.

As illustrated in [Fig. 2](#fig2){ref-type="fig"} , with the isatin as the core structure of our drug design, this strategy would allow us to start with the modification of the substitution pattern of the benzene ring, especially at C-5, followed by N-derivatization and then C-3 variation.Fig. 2Structure modifications of isatin derivatives for SAR study.Fig. 2

The *in vitro* antitumor activities of the 5-substituted isatins **1a-1k** against two human tumor cells K562 and HepG2 were first evaluated. As shown in [Table 1](#tbl1){ref-type="table"} , the cytotoxic activities of the 5-phenyl substituted compounds are far better than the parent nucleus. Among them, compound **1i** exhibited the highest cytotoxic activity against HepG2 cell lines (IC~50~ = 0.96 μM).Table 1In *vitro* antitumor activities of compounds **1a**-**1k**\[14\].Table 1Compd.R; R1IC~50~(μM)K562HepG2**CPT**0.07 ± 0.010.37 ± 0.06**1a**H\>10\>10**1b**F\>10\>10**1c**Cl\>10\>10**1d**Br\>10\>10**1e**CH~3~\>10\>10**1f**OCH~3~\>10\>10**1g**(CH~2~)~3~CH~3~\>10\>10**1h**CH~3~\>106.00 ± 2.16**1i**OCH~3~6.92 ± 0.280.96 ± 0.32**1j**H\>105.33 ± 0.62**1k**CF~3~\>105.43 ± 1.45

After compound **1i** was identified as the potential lead, our SAR study was then focused on the N-derivatization based on the hypothesis that the combination of C-5 substitution with N-alkylation may further enhance their cytotoxic potency. A series of 5-(4-methoxyphenyl) N-substituted derivatives ([Scheme 1](#sch1){ref-type="fig"}) were screened for their *in vitro* cytotoxic activity.

As can be seen from the data in [Table 2](#tbl2){ref-type="table"} , introduction of simple aliphatic groups at N-1 (**2a-2c**) did not significantly enhance their potency. Moreover, a *p*-methoxyphenyl group at N-1 significantly diminished the potency. However, the introduction of benzyl groups into the N-1 position (**2d-2v**) resulted in much better inhibitory activities, with 10--300 folds improvement compared to that of **1i**, pointing to the tendency that the N-1 position needs a relatively sterically larger group with certain lipophilic property to increase the potency. Further examination of the structure difference and the cytotoxic data of the compounds **2d** and **2f-2v** against K562 showed that the substituted benzyl group did increase the potency. The improvement in potency does not seem to be related to the electron density of the substituent groups (**2f**, **2r** and **2h**, **2l**); however, the substituents\' size (**2k**, **2p**) and location (**2n** and **2m**, **2o**) plays a more significant role. Moreover, the excellent cytotoxic activity for the compounds containing N-1 para or ortho mono methoxy benzyl group (**2m**, **2o**), dimethoxy benzyl group (**2q**) as well as a piperonyl group (**2v**) indicated that hydrogen bond receptor in this direction of the molecule could significantly enhance the potency (8--25 folds, compared to that of **2d**).Table 2In *vitro* antitumor activities of compounds **2a**-**2v**.Table 2Compd.R2IC~50~(μΜ)K562HepG2**CPT**0.07 ± 0.010.37 ± 0.06**1i**H6.92 ± 0.280.96 ± 0.32**2a**CH~3~4.98 ± 0.926.67 ± 2.82**2b**CH~2~CH~3~2.20 ± 0.364.47 ± 0.23**2c**CH~2~CH=CH~2~0.39 ± 0.057.09 ± 1.04**2d**CH~2~C~6~H~5~0.57 ± 0.111.36 ± 0.51**2e**C~6~H~4~-4-OCH~3~\>10\>10**2f**CH~2~-4-C~6~H~4~F0.56 ± 0.081.12 ± 0.33**2g**CH~2~-3,4-C~6~H~3~Cl~2~0.43 ± 0.150.99 ± 0.02**2h**CH~2~-4-C~6~H~4~Cl0.35 ± 0.130.25 ± 0.09**2i**CH~2~-3-C~6~H~4~Cl0.20 ± 0.120.32 ± 0.12**2j**CH~2~-2-C~6~H~4~Cl0.38 ± 0.200.60 ± 0.24**2k**CH~2~-4-C~6~H~4~Br0.10 ± 0.150.70 ± 0.03**2l**CH~2~-4-C~6~H~4~CH~3~0.27 ± 0.030.33 ± 0.03**2m**CH~2~-4-C~6~H~4~OCH~3~0.03 ± 0.010.05 ± 0.03**2n**CH~2~-3-C~6~H~4~OCH~3~0.68 ± 0.270.70 ± 0.18**2o**CH~2~-2-C~6~H~4~OCH~3~0.04 ± 0.010.13 ± 0.02**2p**CH~2~-3,4-C~6~H~3~(CH~3~)~2~0.14 ± 0.030.41 ± 0.03**2q**CH~2~-3,4C~6~H~3~(OCH~3~)~2~0.06 ± 0.011.35 ± 1.86**2r**CH~2~-4-C~6~H~4~CN0.38 ± 0.071.00 ± 0.29**2s**CH~2~-4-C~6~H~4~CF~3~0.27 ± 0.030.38 ± 0.02**2t**CH~2~CH~2~OC~6~H~5~0.40 ± 0.060.70 ± 0.25**2u**CH~2~-2-naphthyl0.40 ± 0.040.38 ± 0.05**2v**CH~2~-2-piperonyl0.03 ± 0.010.44 ± 0.19

With the identification of the p-methoxybenzyl group as an optimal substituent at N-1, our attention then turned back to the p-methoxyphenyl substitution on the benzene ring. Specifically, we were interested in finding out how the location would influence the cytotoxic potency. For this purpose, a series of isatins bearing p-methoxyphenyl group(s) at various position on the benzene ring were synthesized and their cytotoxic activities were examined. The compounds **3a-3c** were synthesized following the procedure similar to that of **2m** ([Scheme 2](#sch2){ref-type="fig"}) and their potency were listed in [Table 3](#tbl3){ref-type="table"} . The 4-, 6- and 7-monosubstituted compounds **3a-3c** exhibited much weaker potency than that of **2m** (\>220 folds), which may suggest that the N-1, C-5 disubstituted pattern in **2m** possess a much favorable 2-dimensional orientation toward the biological targets.Table 3In *vitro* antitumor activities of compounds **3a**-**3c**.Table 3Compd.PositionIC~50~(μM)K562HepG2**CPT**0.07 ± 0.010.37 ± 0.06**2m**50.03 ± 0.010.05 ± 0.03**3a**4\>10\>10**3b**67.46 ± 1.69\>10**3c**74.43 ± 0.758.56 ± 0.06

The SAR analysis of the compounds in [Table 3](#tbl3){ref-type="table"} revealed that the N-(p-methoxybenzyl) and 5-(p-substituted phenyl) disubstituted isatins are the most attractive candidates, with compound **2m** exhibiting the highest potency. To further investigate the activity of the structural analogues of **2m**, a number of 5-aryl N-(p-methoxyphenyl)satins were prepared ([Scheme 3](#sch3){ref-type="fig"}) and their inhibition against two human tumor cells were tested ([Table 4](#tbl4){ref-type="table"} ).Table 4In *vitro* antitumor activities of compounds **4a**-**4r**.Table 4Compd.R3IC~50~(μΜ)K562HepG2**CPT**0.07 ± 0.010.37 ± 0.06**2m**C~6~H~4~-4-OCH~3~0.03 ± 0.010.05 ± 0.03**4a**C~6~H~4~-3-OCH~3~0.10 ± 0.031.89 ± 1.48**4b**C~6~H~4~-2-OCH~3~0.37 ± 0.09\>10**4c**C~6~H~4~-3,5-(OCH~3~)~2~0.51 ± 0.211.20 ± 0.58**4d**C~6~H~4~-3,4-(OCH~3~)~2~0.26 ± 0.11\>10**4e**C~6~H~4~-4-CC~3~H~9~2.25 ± 0.734.58 ± 1.09**4f**C~6~H~4~-4-F0.24 ± 0.113.15 ± 2.31**4g**C~6~H~4~-4-Cl0.23 ± 0.050.38 ± 0.21**4h**C~6~H~3~-3-Cl-4-F0.38 ± 0.08\>10**4i**C~6~H~4~-4-CH~3~^a^0.40 ± 0.12\>10**4j**C~6~H~4~-4-(O-Pr)0.31 ± 0.08\>10**4k**C~6~H~5~0.15 ± 0.021.08 ± 0.60**4l**C~6~H~4~-4-CN^a^0.26 ± 0.040.89 ± 0.11**4m**C~6~H~4~-4-CF~3~^a^0.35 ± 0.080.82 ± 0.20**4n**C~6~H~4~-4-OCF~3~^a^0.06 ± 0.010.41 ± 0.32**4o**C~6~H~4~-4-OH^a^0.06 ± 0.02\>10**4p**2-naphthyl0.34 ± 0.10\>10**4q**4-pyridyl0.04 ± 0.02\>10**4r**2-thiophenyl0.08 ± 0.043.67 ± 1.40

As shown in [Table 4](#tbl4){ref-type="table"}, among all the 18 compounds examined, the cytotoxic activities of the phenyl analogue **4k**, region-isomers **4a**, **4b** as well as the 3,5-dimethoxy-phenyl substituted compounds **4c** exihibted a 5--25 folds decrease in potency compared to **2m**, indicating that the para methoxy group is necessary and its linear orientation maybe a critical factor in maintaining its high potency.

The halogen-containing compounds (**4f**, **4g**, **4h**), compounds (**4i**, **4j**, **4l**, **4m**) possess either electron-donating or electron-withdrawing groups, all exhibit very similar inhibition, indicating that variation of the electron density at this position did not significantly change their potency.

The excellent potency 5-(4-pyridyl) substituted compound **4q** and 5-(2-thiophenyl) substituted compound **4r** suggest that groups possessing a Lewis basic site could potentially improve the compound\'s activity. The hydroxyl group containing compound **4o** did not exhibit any improved activity in comparison to compounds 2**m**, **4q** and **4r**.

There was no significant potency change when the 5-phenyl substitution (**4k**) was replaced by 5-(4-methyphenyl) group (**4i**) or 5-(2-naphthyl) group (**4p**). However, the cytotoxic activity of the 5-(4-n-butyl)phenyl compound **4e** dropped 15 folds from that of the non-substituted counterpart (**4k**), which indicated the bulky aliphatic chain is detrimental.

Derivatization of the C-3 ketone group of **2m** led to compounds **5a-5l** ([Scheme 4](#sch4){ref-type="fig"}) and their cytotoxic activities were evaluated to establish the importance of this functionality. The testing result showed that all these derivatives are inferior candidates as inhibitors of K562 and HepG2 ([Table 5](#tbl5){ref-type="table"} ), suggesting that the carbonyl functionality at C-3 is essential in order to maintain the observed high antitumor activity.Table 5Antitumor activity of the C-3 derivatized compounds **5a**-**5k**.Table 5Compd.C-3IC~50~(μM)K562HepG2**CPT**0.07 ± 0.010.37 ± 0.06**2m** = O0.03 ± 0.010.05 ± 0.03**5a**-OH·H0.14 ± 0.090.70 ± 0.03**5b**-OH·CH~3~\>10\>10**5c**-H·H\>10\>10**5d** = COOCH~2~CH~3~1.24 ± 0.543.39 ± 0.27**5e** = COOCH~3~1.90 ± 0.144.73 ± 1.24**5f**-CH~2~O(CH~2~)~2~OCH~2~-\>10\>10**5g**-F·F\>10\>10**5h** = NOH\>10\>10**5i** = C~6~H~5~\>10\>10**5j** = C~6~H~4~-4-CF~3~1.90 ± 0.26\>10**5k** = C~6~H~4~-4-CH(CH~3~)~2~\>10\>10

Based on these SAR studies, compound **2m** exhibited significant cancer inhibitory activity *in vitro* against the tested cancer cell lines. The IC~50~ of compounds **2m** against K562 cells and HepG2 cells were 30 nM and 50 nM, respectively ([Fig. 3](#fig3){ref-type="fig"} A). Meanwhile, a normal human cell line (umbilical vein endothelial cells, HUVEC) has been tested for 2m, the IC~50~ was 920 nM. Then the molecular mechanism by which compound **2m** exerts its cytotoxic activity on cells proliferation, migration and angiogenesis was further investigated.Fig. 3Morphological changes in compound **2m-**treated K562 cells. (A) Structure and *in vitro* cell proliferation inhibitory activity of compound **2m**. (B) Morphological changes induced by compound **2m** treatment (30 nM) were observed.Fig. 3

Firstly, the morphological changes in compound **2m**-treated K562 cells were observed. K562 cells treated by compound **2m** showed the cells morphology change of G~2~/M phase arrest (such as elongation of the cells) and typical apoptotic morphology (such as cell shrinkage and/or blebbing) ([Fig. 3](#fig3){ref-type="fig"}B). As shown in [Fig. 3](#fig3){ref-type="fig"}B, the elongated cells increased significantly as early as 6 h after compound **2m** treatment at a concentration of 30 nM as compared to DMSO-treated cells. The apoptotic cells were clearly observed in K562 cells after the treatment with compound **2m** for 24 h. These results indicated that compound **2m** might inhibit the cell proliferation of K562 cells through the cell cycle arrest and apoptosis.

To evaluate the cell cycle distribution of K562 cells with or without compound **2m** treatment, we measured the DNA content by flow cytometry. As shown in [Fig. 4](#fig4){ref-type="fig"} , after treatment with compound **2m** (30 and 300 nM) for 48 h, the percentage of K562 cells in G~2~/M phase increased. Only 0.02% of cells were in G~2~/M phase in basic DMSO cultures. However, the exposure to compound **2m** caused increased cell fraction in G~2~/M phase in a time-dependent and dose-dependent manner. These results demonstrated that compound **2m** has cell proliferation inhibitory effect and can induce the cell cycle arrest of K562 cells in G~2~/M phase.Fig. 4Compound **2m** induced the cell cycle arrest of K562 cells in G~2~/M phase. K562 cells were treated with 30 nM and 300 nM compound **2m**. At the time points indicated, cells were labeled with PI and their DNA content was determined using FACS analysis.Fig. 4

The presence of apoptotic K562 cells following compound **2m** treatment was further revealed by flow cytometric analysis of cells double-labeled with Annexin V-FITC and PI ([Fig. 5](#fig5){ref-type="fig"} ). After 48 h of treatment with compound **2m** (30 and 300 nM), we observed that compound **2m** showed significant apoptosis against K562 cells. The apoptotic rates of compound **2m**-treated K562 cells increased to 43.4% and 95.2% of the total cells whereas only 4.1% and 4.3% apoptosis respectively at 30 nM and 300 nM. Result also indicated that the apoptosis was increased obviously in a time-dependent and dose-dependent manner. We have concluded that compound **2m** inhibits the proliferation of K562 cells by inducing apoptosis in a time-dependent and dose-dependent manner.Fig. 5Compound **2m** induced apoptosis in K562 cells. K562 cells were treated with 30 nM and 300 nM compound **2m** for different periods of time. K562 cells were labeled with Annexin V-FITC and PI and apoptosis was determined using FACS analysis.Fig. 5

To study whether compound **2m** could inhibit migration and repair ability of tumor cells, wound healing assay and transwell assay were performed by HepG2 cells. After HepG2 cells were wounded, they were treated with the indicated concentrations of compound **2m** (10 nM, 30 nM, 100 nM) for 0, 6, 12, 24, 36 and 48 h respectively. As shown in [Fig. 6](#fig6){ref-type="fig"} A, after treatment by DMSO for 48 h, the migration distance was 184.89 μm. The migration distances of HepG2 cells treated with compound **2m** were 162.89 μm, 135.22 μm and 96.24 μm respectively at 10 nM, 30 nM and 100 nM. By calculation, we found that the higher concentration of compound **2m**, the higher the inhibition ratio. The inhibition ratios of HepG2 cells treated with compound **2m** were 11.9%, 26.9% and 47.9% respectively at 10 nM, 30 nM and 100 nM.Fig. 6Effect of compound **2m** on HepG2 cells migration at 48 h by using a wound healing assay (A) and transwell assay (B).Fig. 6

Transwell assay is an experimental technique for studying the tendency of cells which is applied in cell culture, cytotaxis, cell migration and cell invasion. As shown in [Fig. 6](#fig6){ref-type="fig"}B, basic DMSO did not affect migration of HepG2 cells. While, the compound **2m** could inhibit the HepG2 cells migration and have a dose-dependent inhibitory effect.

Tube formation plays an important role in the development of tumors. Angiogenesis is also the path which tumors transition from benign to malignant. Inhibiting this process can significantly prevent the development and spread of tumor tissue. As shown in [Fig. 7](#fig7){ref-type="fig"} , basic DMSO did not affect tube forming of HUVEC cells. However, the compound **2m** could inhibit the angiogenesis of HUVEC cells and have a dose-dependent inhibitory effect.Fig. 7Suppressive effects of different concentrations compound **2m** on tube formation of HUVEC cells. HUVECs cultured on matrigel coated plates were treated with the indicated concentrations of compound **2m** (10 nM, 30 nM, 100 nM) for 12 h. Morphological changes in HUVECs were observed by microscopy and representative images are shown.Fig. 7

4. Conclusions {#sec4}
==============

In conclusion, a series of novel N-1 benzyl and C-5 phenyl substituted isatin derivatives were synthesized and tested for their *in vitro* antitumor activity against two strains of cancer cell lines (human leukemia K562 cells and liver cancer HepG2 cells). Among them, compounds **2m** exhibited excellent cancer inhibitory activity *in vitro* against K562 cell lines (IC~50~ = 0.03 μM) and HepG2 cell lines (IC~50~ = 0.05 μM). SAR analysis showed that the carbonyl group of the isatin, N-benzyl and C-5 phenyl substituted pattern, the *para*-methoxyl group of the benzyl played a significant role in the antitumor activity.

Both morphological results and flow cytometry analysis showed that compound **2m** induce apoptosis and cause cell cycle arrest in a time-dependent and dose-dependent manner. Furthermore, wound healing and transwell experiments showed that compound **2m** could inhibit the migration and repair ability of HepG2 cells. In addition, the results of cell tube formation showed that the compound **2m** could inhibit the angiogenesis of HUVEC cells and has a dose-dependent inhibitory effect.

The effects of indole derivative compound **2m** on tumor cell growth, migration and angiogenesis were studied, which provide a strong foundation for further study on the antitumor activity and mechanism of indole compounds.

5. Experimental section {#sec5}
=======================

5.1. Chemistry {#sec5.1}
--------------

All reagents and solvents used in this paper were of reagent grade, were obtained from commercial suppliers and used without further purification. ^1^H NMR and ^13^C NMR spectra were recorded on a Bruker AM-400 NMR spectrometer (Billerica, Middlesex, MA, USA) in CDCl~3~ or DMSO‑*d* ~6~. The chemical shifts are reported in *δ*(ppm) relative to tetramethylsilane as internal standard. (^1^H NMR: TMS at 0.00 ppm, CDCl~3~ at 7.26 ppm, DMSO‑*d* ~6~ at 2.50 ppm; ^13^C NMR: CDCl~3~ at 77.23 ppm, DMSO‑*d* ~6~ at 39.51 ppm). Mass spectra were obtained on a Q-TOF mass spectrometer (Agilent, Santa Clara, CA, USA). TLC analyses were carried out on silica gel F254, and the spots were examined with UV light. All final products had a purity of ≥95%. The purity of the final products was determined by HPLC (LabTech) on a Diamonsil C18 column (4.6 mm × 250 mm, 5 μm) with methanol/H~2~O (90/10 v/v) at 0.5 mL/min flow rate and 254 nm detector wavelength.

5.2. Synthesis of compounds **1a-1k** and **2a-2v** {#sec5.2}
---------------------------------------------------

The general procedure for the preparation of isatin derivatives was as follows. A mixture of 0.05 mol substituted anilines, 0.15 mol Hydroxylammonium chloride, 0.35 mol Na~2~SO~4~, 2 mol/L Hydrochloric acid at 5 mL and Chloral hydrate at 0.06 mol were stirred in 250 mL H~2~O at 95 °C. The progress of the reaction was monitored by TLC (petroleum ether/ethyl acetate). After the reaction was completed, the reaction mixture was cooled to room temperature and the precipitate was filtered and dried. The crude product was used directly for the next step without further purification.

To a flask (100 mL) which contained concentrated sulfuric acid (20 mL) was added N-2-(hydroxyimino)acetamide derivatives (7.0 g) in portions at 50 °C with vigorous stirring. The reaction temperature was maintained at 50 °C-75 °C during the addition. After the addition was completed, the mixture was heated to 80 °C and stir at 80 °C for 30 min. The reaction mixture was cooled to room temperature and then poured onto ice (250 g). The solid which resulted was filtered out and dried over air to yield the crude which was purified by dissolving in dilute sodium hydroxide (5%, 100 mL) followed by acidified with 4N hydrochloric acid (20 mL). The solid which formed was filtered out and dried over air to provide the purified compounds **1a-1g**.

To a microwave reactor vial (5 mL) which contained the solution of 5-bromoindoline-2,3-dione (1.0 g, 4.4 mmol) in 1,4-dioxane (5 mL) were added PdCl~2~(dppf) (161 mg, 0.22 mmol), CH~3~COOK (0.6 g, 6.2 mmol) and substituted benzeneboronic acid (0.45 g, 5.3 mmol) under the atmosphere of argon. The microwave reactor vial was caped and placed into the microwave cavity. The reaction mixture was irradiated at high level for 30 min at 120 °C. The reaction mixture was cooled to room temperature, poured onto 100 mL ice-water and then extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with water (2 × 100 mL), brine (100 mL) and dried over anhydrous magnesium sulfate. The solvent was removed under vacuum to afford the crude which was purified by flash column chromatography (silica gel, petroleum ether/ethyl acetate 3:1) to yield the desired compound **1h-1k**.

To a flask (25 mL) which contained the solution of compound **1i** (0.2 g, 0.79 mmol) in dry N,N-dimethylformamide (2 mL). The reaction temperature was maintained at 0 °C followed by addition K~2~CO~3~ (0.33 g, 2.37 mmol). Stirring 5 min, was added alkyl or benzyl (1.0 mmol) and the mixture allowed warm to room temperature. The reaction mixture was stirred at room temperature for 4 h. The orange solution was poured water (25 mL) and extracted with dichloromethane (3 × 100 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 10:1--3:1) afforded the title compounds **2a-2v**.

### 5.2.1. 5-(p-tolyl)indoline-2,3-dione **(1h)** {#sec5.2.1}

Yield 54%; ^1^H NMR (400 MHz, DMSO‑*d* ~6~) *δ* 2.36 (s, 3H), 6.98 (d, 1H, *J* = 8.0 Hz), 7.25 (d, 2H, *J* = 8.0 Hz), 7.53 (d, 2H, *J* = 8.0 Hz), 7.72 (s, 1H), 7.87 (d, 1H, *J* = 8.0 Hz), 11.11 (s, 1H). ^13^C NMR (100 MHz, DMSO‑*d* ~6~) *δ* 21.10, 113.10, 118.84, 122.62, 126.50, 126.50, 130.05, 130.05, 135.34, 136.31, 136.64, 137.27, 150.17, 160.00, 184.86. ESI-MS: 238.1 \[M+H\]+, 260.1\[M+Na\]+.

### 5.2.2. 5-(4-methoxyphenyl)indoline-2,3-dione **(1i)** {#sec5.2.2}

Yield 55%; ^1^H NMR (400 MHz, DMSO‑*d* ~6~) *δ* 3.79 (s, 3H), 6.97 (d, 1H, *J* = 8.0 Hz), 7.00 (d, 2H, *J* = 8.0 Hz), 7.59 (d, 2H, *J* = 8.0 Hz), 7.70 (s, 1H), 7.84 (d, 1H, *J* = 8.0 Hz), 11.09 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 55.65, 113.08, 114.88, 114.88, 118.84, 122.38, 127.83, 127.83, 131.57, 135.18, 136.40, 149.84, 159.38, 160.01, 184.92. ESI-MS: 254.0 \[M+H\]+, 276.0\[M+Na\]+.

### 5.2.3. 5-phenylindoline-2,3-dione **(1j)** {#sec5.2.3}

Yield 43%; ^1^H NMR (400 MHz, DMSO‑*d* ~6~) *δ* 7.01 (d, 1H, *J* = 8.0 Hz), 7.36--7.38 (m, 1H), 7.44--7.47 (m, 2H), 7.64--7.66 (m, 2H), 7.76 (s, 1H), 7.89--7.92 (m, 1H), 11.13 (s, 1H). ^13^C NMR (100 MHz, DMSO‑*d* ~6~) *δ* 112.65, 118.37, 122.40, 126.18, 126.18, 127.44, 128.97, 128.97, 134.88, 136.44, 138.68, 149.91, 159.51, 184.32. ESI-MS: 224.1 \[M+H\]+, 246.1\[M+Na\]+.

### 5.2.4. 5-(4-(trifluoromethyl)phenyl)indoline-2,3-dione **(1k)** {#sec5.2.4}

Yield 44%; ^1^H NMR (400 MHz, DMSO‑*d* ~6~) *δ* 7.04 (d, 1H, *J* = 8.0 Hz), 7.79 (d, 2H, *J* = 8.4 Hz), 7.87 (s, 1H), 7.90 (d, 2H, *J* = 8.0 Hz), 7.99 (d, 1H, *J* = 8.4 Hz), 11.20 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 102.01, 111.59, 113.26, 119.03, 123.40, 126.26, 126.29, 127.48, 127.48, 133.59, 137.24, 143.19, 151.15, 160.01, 184.63. ESI-MS: 292.0 \[M+H\]+.

### 5.2.5. 5-(4-methoxyphenyl)-1-methylindoline-2,3-dione **(2a)** {#sec5.2.5}

Yield 44%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.28 (s, 3H), 3.85 (s, 3H), 6.94 (d, 1H, *J* = 8.0 Hz), 6.98 (d, 2H, *J* = 8.4 Hz), 7.46 (d, 2H, *J* = 8.4 Hz), 7.78 (d, 1H, *J* = 8.0 Hz), 7.79 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 26.33, 55.40, 110.23, 114.50, 114.50, 117.87, 123.26, 127.64, 127.64, 131.43, 136.28, 137.09, 149.96, 158.38, 159.59, 183.55. ESI-MS: 268.1 \[M+H\]+, 290.1 \[M+Na\]+.

### 5.2.6. 1-ethyl-5-(4-methoxyphenyl)indoline-2,3-dione **(2b)** {#sec5.2.6}

Yield 35%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 1.32--1.35 (m, 3H), 3.78--3.84 (m, 2H), 3.85 (s, 3H), 6.95 (d, 1H, *J* = 8.0 Hz), 6.97 (d, 2H, *J* = 8.8 Hz), 7.45 (d, 2H, *J* = 8.8 Hz), 7.74 (s, 1H), 7.76 (d, 1H, *J* = 8.0 Hz). ^13^C NMR (100 MHz, CDCl~3~) *δ* 12.60, 35.08, 55.40, 110.33, 114.50, 114.50, 118.06, 123.47, 127.63, 127.63, 131.47, 136.24, 136.90, 149.16, 158.00, 159.57, 183.91. ESI-MS: 282.1 \[M+H\]+, 304.1 \[M+Na\]+.

### 5.2.7. 1-allyl-5-(4-methoxyphenyl)indoline-2,3-dione **(2c)** {#sec5.2.7}

Yield 42%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.85 (s, 3H), 4.40 (d, 2H, *J* = 5.6 Hz), 5.30--5.37 (m, 2H), 5.82--5.96 (m, 1H), 6.94 (d, 1H, *J* = 8.0 Hz), 6.96 (d, 2H, *J* = 8.8 Hz), 7.45 (d, 2H, *J* = 8.8 Hz), 7.73 (d, 1H, *J* = 8.0 Hz), 7.80 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 42.62, 55.40, 111.17, 114.52, 114.52, 118.02, 118.70, 123.39, 127.67, 127.67, 130.41, 131.49, 136.24, 137.10, 149.34, 158.05, 159.61, 183.44. ESI-MS: 294.1 \[M+H\]+, 316.1 \[M+Na\]+.

### 5.2.8. 1-benzyl-5-(4-methoxyphenyl)indoline-2,3-dione **(2d)** {#sec5.2.8}

Yield 40%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.83 (s, 3H), 4.95 (s, 2H), 6.81 (d, 1H, *J* = 8.4 Hz), 6.95 (d, 2H, *J* = 8.4 Hz), 7.29--7.36 (m, 5H), 7.40 (d, 2H, *J* = 8.4 Hz), 7.64 (d, 1H, *J* = 8.4 Hz), 7.78 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 44.16, 55.38, 111.30, 114.50, 114.50, 118.12, 123.38, 127.47, 127.47, 127.63, 127.63, 128.20, 129.08, 129.08, 131.42, 134.57, 136.23, 137.14, 149.22, 158.41, 159.60, 183.44. ESI-MS: 344.1 \[M+H\]+, 366.1 \[M+Na\]+.

### 5.2.9. 1,5-bis(4-methoxyphenyl)indoline-2,3-dione **(2e)** {#sec5.2.9}

Yield 45%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.85 (s, 3H), 3.87 (s, 3H), 6.88 (d, 1H, *J* = 8.0 Hz), 6.98 (d, 2H, *J* = 8.0 Hz), 7.07 (d, 2H, *J* = 8.0 Hz), 7.35 (d, 2H, *J* = 8.0 Hz), 7.46 (d, 2H, *J* = 8.0 Hz), 7.70 (d, 1H, *J* = 8.0 Hz), 7.85 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 55.41, 55.62, 111.50, 114.53, 114.53, 115.25, 115.25, 117.90, 123.40, 125.50, 127.39, 127.39, 127.69, 127.69, 131.45, 136.27, 137.45, 150.59, 157.76, 159.65, 159.72, 183.34. ESI-MS: 360.1 \[M+H\]+, 382.1 \[M+Na\]+.

### 5.2.10. 1-(4-fluorobenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2f)** {#sec5.2.10}

Yield 42%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.83 (s, 3H), 4.92 (s, 2H), 6.81 (d, 1H, *J* = 8.4 Hz), 6.95 (d, 2H, *J* = 8.8 Hz), 7.02--7.07 (m, 2H), 7.32--7.36 (m, 2H), 7.40 (d, 2H, *J* = 8.8 Hz), 7.66 (d, 1H, *J* = 8.4 Hz), 7.78 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.47, 55.39, 111.12, 114.51, 114.51, 115.96, 116.17, 118.13, 123.49, 127.64, 127.64, 129.26, 129.35, 130.38, 130.42, 131.33, 136.24, 137.29, 148.95, 158.36, 159.63, 183.28. ESI-MS: 362.2 \[M+H\]+, 384.2 \[M+Na\]+.

### 5.2.11. 1-(3,4-dichlorobenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2g)** {#sec5.2.11}

Yield 34%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 4.90 (s, 2H), 6.78 (d, 1H, *J* = 8.0 Hz), 6.97 (d, 2H, *J* = 8.4 Hz), 7.20 (d, 1H, *J* = 8.4 Hz), 7.42 (d, 2H, *J* = 8.0 Hz), 7.44 (d, 2H, *J* = 8.0 Hz), 7.69 (d, 1H, *J* = 8.0 Hz), 7.81 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.11, 55.39, 110.89, 114.56, 114.56, 118.19, 123.68, 126.74, 127.67, 127.67, 129.40, 131.13, 131.27, 132.58, 133.35, 134.86, 136.32, 137.60, 148.57, 158.33, 159.72, 182.85. ESI-MS: 412.1 \[M+H\]+.

### 5.2.12. 1-(4-chlorobenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2h)** {#sec5.2.12}

Yield 43%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 4.92 (s, 2H), 6.78 (d, 1H, *J* = 8.0 Hz), 6.96 (d, 2H, *J* = 8.4 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.34 (d, 2H, *J* = 8.4 Hz), 7.41 (d, 2H, *J* = 8.4 Hz), 7.66 (d, 1H, *J* = 8.0 Hz), 7.79 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.52, 55.39, 111.11, 114.52, 114.52, 118.13, 123.52, 127.65, 127.65, 128.87, 128.87, 129.30, 129.30, 131.31, 133.10, 134.16, 136.26, 137.35, 148.86, 158.37, 159.64, 183.18. ESI-MS: 378.0 \[M+H\]+.

### 5.2.13. 1-(3-chlorobenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2i)** {#sec5.2.13}

Yield 40%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 4.93 (s, 2H), 6.80 (d, 1H, *J* = 8.0 Hz), 6.96 (d, 2H, *J* = 8.8 Hz), 7.27 (d, 2H, *J* = 8.4 Hz), 7.32 (d, 2H, *J* = 8.4 Hz), 7.42 (d, 2H, *J* = 8.8 Hz), 7.68 (d, 1H, *J* = 8.0 Hz), 7.81 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.61, 55.39, 111.01, 114.52, 114.52, 118.13, 123.58, 125.56, 127.53, 127.67, 127.67, 128.51, 130.42, 131.32, 135.04, 136.34, 136.64, 137.41, 148.83, 158.37, 159.64, 183.11. ESI-MS: 378.1 \[M+H\]+.

### 5.2.14. 1-(2-chlorobenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2j)** {#sec5.2.14}

Yield 44%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 5.08 (s, 2H), 6.81 (d, 1H, *J* = 8.4 Hz), 6.96 (d, 2H, *J* = 8.0 Hz), 7.23--7.26 (m, 2H), 7.41--7.45 (m, 4H), 7.66 (d, 1H, *J* = 8.0 Hz), 7.81 (s, 1H). ^13^C NMR (100 MHz, CDCl3) *δ* 41.53, 55.39, 111.35, 114.51, 118.10, 123.31,127.50,127.61, 128.34, 129.43, 129.98, 131.26, 131.88, 133.03, 136.40, 137.23, 148.95, 158.56, 159.61, 183.16. ESI-MS: 378.2 \[M+H\]+.

### 5.2.15. 1-(4-bromobenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2k)** {#sec5.2.15}

Yield 45%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 4.90 (s, 2H), 6.78 (d, 1H, *J* = 8.4 Hz), 6.96 (d, 2H, *J* = 8.8 Hz), 7.24 (d, 2H, *J* = 8.4 Hz), 7.41 (d, 2H, *J* = 8.8 Hz), 7.49 (d, 2H, *J* = 8.4 Hz), 7.66 (d, 1H, *J* = 8.0 Hz), 7.80 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.58, 55.39, 111.10, 114.52, 114.52, 118.14, 122.24, 123.55, 127.66, 127.66, 129.17, 129.17, 131.32, 132.26, 132.26, 133.61, 136.27, 137.39, 148.84, 158.36, 159.65, 183.15. ESI-MS: 422.1 \[M+H\]+.

### 5.2.16. 5-(4-methoxyphenyl)-1-(4-methylbenzyl)indoline-2,3-dione **(2l)** {#sec5.2.16}

Yield 43%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 2.33 (s, 3H), 3.84 (s, 3H), 4.91 (s, 2H), 6.82 (d, 1H, *J* = 8.0 Hz), 6.95 (d, 2H, *J* = 8.8 Hz), 7.16 (d, 2H, *J* = 8.0 Hz), 7.25 (d, 2H, *J* = 8.0 Hz), 7.40 (d, 2H, *J* = 8.8 Hz), 7.64 (d, 1H, *J* = 8.0 Hz), 7.78 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 21.13, 43.94, 55.38, 111.33, 114.49, 114.49, 118.12, 122.44, 123.37, 127.50, 127.50, 127.63, 127.63, 129.73, 129.73, 131.49, 136.22, 137.08, 138.02, 149.29, 158.39, 159.57, 183.57. ESI-MS: 358.2 \[M+H\]+.

### 5.2.17. 1-(4-methoxybenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2m)** {#sec5.2.17}

Yield 50%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.78 (s, 3H), 3.83 (s, 3H), 4.88 (s, 2H), 6.84 (d, 1H, *J* = 8.4 Hz), 6.87 (d, 2H, *J* = 8.4 Hz), 6.95 (d, 2H, *J* = 8.8 Hz), 7.28 (d, 2H, *J* = 8.4 Hz), 7.39 (d, 2H, *J* = 8.8 Hz), 7.64 (d, 1H, *J* = 8.4 Hz), 7.76 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.64, 55.30, 55.38, 111.32, 114.45, 114.45, 114.49, 114.49, 118.12, 123.32, 126.55, 127.61, 127.61, 128.96, 128.96, 131.43, 136.18, 137.04, 149.26, 158.37, 159.50, 159.58, 183.59; IR (KBr) 3435 (C~Ar~-H), 2982, 2887, 1727 (C=O), 1618 (C=O), 1513 (C~Ar~=C~Ar~), 1480 (C~Ar~=C~Ar~), 1035 (C-O), 821 (C~Ar~-H) cm^−1^; ESI-MS: 374.2 \[M+H\]+, 396.1 \[M+Na\]+. HRMS (ESI, *m*/*z*): calcd for C~23~ H~19~ N O~4~Na \[M+Na\]^+^ 396.1206, found 396.1195.

### 5.2.18. 1-(3-methoxybenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2n)** {#sec5.2.18}

Yield 40%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 3.83 (s, 3H), 4.92 (s, 2H), 6.83 (d, 1H, *J* = 8.4 Hz), 6.87 (d, 2H, *J* = 8.4 Hz), 6.96 (d, 2H, *J* = 8.0 Hz), 6.97 (s, 1H), 7.28 (d, 1H, *J* = 8.0 Hz), 7.41 (d, 2H, *J* = 8.4 Hz), 7.65 (d, 1H, *J* = 8.0 Hz), 7.79 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 44.12, 55.31, 55.39, 111.34, 113.28, 113.38, 114.50, 114.50, 118.10, 119.68, 123.39, 127.64, 127.64, 130.14, 131.44, 136.12, 136.28, 137.16, 149.24, 158.40, 159.59, 160.16, 183.43. ESI-MS: 374.2 \[M+H\]+, 396.2 \[M+Na\]+.

### 5.2.19. 1-(2-methoxybenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2o)** {#sec5.2.19}

Yield 42%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.83 (s, 3H), 3.90 (s, 3H), 4.97 (s, 2H), 6.90--6.96 (m, 5H), 7.29 (d, 2H, *J* = 8.4 Hz), 7.41 (d, 2H, *J* = 8.4 Hz),7.65 (d, 1H, *J* = 8.0 Hz), 7.69 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 38.98, 55.38, 55.46, 110.62, 111.54, 114.47, 114.47, 118.07, 120.92, 122.53, 123.14, 127.62, 127.62, 129.00, 129.39, 131.57, 136.27, 136.84, 149.71, 157.15, 158.56, 159.52, 183.82. ESI-MS: 374.2 \[M+H\]+, 396.2 \[M+Na\]+.

### 5.2.20. 1-(3,5-dimethylbenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2p)** {#sec5.2.20}

Yield 46%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 2.29 (s, 6H), 3.84 (s, 3H), 4.86 (s, 2H), 6.83 (d, 1H, *J* = 8.0 Hz), 6.93--6.96 (m, 5H), 7.41 (d, 2H, *J* = 8.8 Hz), 7.65 (d, 1H, *J* = 8.0 Hz), 7.78 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 21.29, 21.29, 44.13, 55.39, 111.37, 114.49, 114.49, 118.11, 123.34, 125.24, 125.24, 127.63, 127.63, 129.85, 131.49, 134.44, 136.28, 137.05, 138.74, 138.74, 149.39, 158.42, 159.57, 183.62. ESI-MS: 372.2 \[M+H\]+, 394.2 \[M+Na\]+.

### 5.2.21. 1-(3,4-dimethoxybenzyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2q)** {#sec5.2.21}

Yield 40%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 3.86 (s, 3H), 3.86 (s, 3H), 4.89 (s, 2H), 6.83 (d, 1H, *J* = 8.4 Hz), 6.86 (d, 2H, *J* = 8.4 Hz), 6.92 (d, 1H, *J* = 8.0 Hz), 6.96 (d, 2H, *J* = 8.8 Hz), 7.41 (d, 2H, *J* = 8.8 Hz), 7.66 (d, 1H, *J* = 8.4 Hz), 7.79 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 44.10, 55.39, 55.93, 56.03, 110.75, 111.25, 111.32, 114.50, 114.50, 118.13, 120.09, 123.42, 127.01, 127.64, 127.64, 131.43, 136.21, 137.15, 149.05, 149.28, 149.60, 158.43, 159.60, 183.56. ESI-MS: 404.1 \[M+H\]+, 426.1 \[M+Na\]+.

### 5.2.22. 4-((5-(4-methoxyphenyl)-2,3-dioxoindolin-1-yl)methyl)benzonitrile **(2r)** {#sec5.2.22}

Yield 29%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 5.01 (s, 2H), 6.74 (d, 1H, *J* = 8.0 Hz), 6.97 (d, 2H, *J* = 8.4 Hz), 7.42 (d, 2H, *J* = 8.4 Hz), 7.47 (d, 2H, *J* = 8.4 Hz), 7.67 (d, 2H, *J* = 8.4 Hz), 7.68 (d, 1H, *J* = 8.0 Hz), 7.82 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.73, 55.40, 110.84, 112.36, 114.56, 114.56, 118.16, 118.25, 123.73, 127.67, 127.67, 128.06, 128.06, 131.16, 132.92, 132.92, 136.35, 137.68, 139.98, 148.49, 158.37, 159.73, 182.76. ESI-MS: 369.1 \[M+H\]+, 391.1 \[M+Na\]+.

### 5.2.23. 5-(4-methoxyphenyl)-1-(4-(trifluoromethyl)benzyl)indoline-2,3-dione **(2s)** {#sec5.2.23}

Yield 41%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 5.01 (s, 2H), 6.77 (d, 1H, *J* = 8.0 Hz), 6.96 (d, 2H, *J* = 8.4 Hz), 7.42 (d, 2H, *J* = 8.4 Hz), 7.48 (d, 2H, *J* = 8.0 Hz), 7.63 (d, 2H, *J* = 8.0 Hz), 7.65 (d, 1H, *J* = 8.0 Hz), 7.82 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.68, 55.40, 110.84, 112.36, 114.56, 114.56, 118.16, 118.25, 123.73, 127.67, 127.67, 128.06, 128.06, 131.16, 132.92, 132.92, 136.35, 137.68, 139.98, 148.49, 158.37, 159.73, 182.76. ESI-MS: 412.2 \[M+H\]+.

### 5.2.24. 5-(4-methoxyphenyl)-1-(2-phenoxyethyl)indoline-2,3-dione **(2t)** {#sec5.2.24}

Yield 41%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.85 (s, 3H), 4.16 (t, 2H, *J* = 10.4 Hz), 4.27 (t, 2H, *J* = 10.4 Hz), 6.845 (d, 2H, *J* = 8.0 Hz), 6.95--6.99 (m, 3H), 7.21--7.28 (m, 4H), 7.46 (d, 2H, *J* = 8.0 Hz), 7.79 (d, 1H, *J* = 8.0 Hz), 7.80 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 40.31, 55.40, 65.72, 111.47, 111.50, 114.37, 114.40, 114.52, 118.03, 121.49, 123.21, 127.67, 127.67, 129.60, 129.60, 131.50, 136.15, 137.07, 149.97, 158.02, 158.63, 159.63, 183.28. ESI-MS: 374.2 \[M+H\]+, 396.2 \[M+Na\]+.

### 5.2.25. 5-(4-methoxyphenyl)-1-(naphthalen-2-ylmethyl)indoline-2,3-dione **(2u)** {#sec5.2.25}

Yield 48%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.83 (s, 3H), 5.12 (s, 2H), 6.84 (d, 1H, *J* = 8.0 Hz), 6.94 (d, 2H, *J* = 8.4 Hz), 7.39 (d, 2H, *J* = 8.8 Hz), 7.44 (d, 1H, *J* = 8.4 Hz), 7.44--7.50 (m, 2H), 7.59--7.62 (m, 1H), 7.80--7.83 (m, 5H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 44.41, 55.37, 113.36, 114.50, 111.50, 118.17, 123.39, 125.04, 126.39, 126.46, 126.63, 127.62, 127.62, 127.77, 127.80, 129.16, 131.41, 131.99, 133.04, 133.32, 136.23, 137.18, 149.22, 158.51, 159.61, 183.42. ESI-MS: 394.2 \[M+H\]+.

### 5.2.26. 1-(benzo\[d\] \[[@bib1],[@bib3]\]dioxol-5-ylmethyl)-5-(4-methoxyphenyl)indoline-2,3-dione **(2v)** {#sec5.2.26}

Yield 46%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.84 (s, 3H), 4.85 (s, 2H), 5.95 (s, 2H), 6.78 (d, 1H, *J* = 8.4 Hz), 6.82--6.86 (m, 3H), 6.96 (d, 2H, *J* = 8.4 Hz), 7.41 (d, 2H, *J* = 8.4 Hz), 7.66 (d, 1H, *J* = 8.0 Hz), 7.78 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 44.00, 55.39, 101.33, 107.98, 108.58, 111.29, 114.50, 114.50, 118.13, 121.11, 123.43, 127.65, 127.65, 128.27, 131.44, 136.23, 137.17, 147.61, 148.35, 149.15, 158.34, 159.60, 183.44. ESI-MS: 388.1 \[M+H\]+, 410.1 \[M+Na\]+.

5.3. Synthesis of compounds **3a-3c** {#sec5.3}
-------------------------------------

To a microwave reactor vial (5 mL) which contained the solution of 4 or 5 or 6 or 7-bromoindoline-2,3-dione in 1,4-dioxane (5 mL) were added PdCl~2~(dppf) (155 mg, 0.22 mmol), CH~3~COOK (0.6 g, 6.2 mmol) and 4-Methoxyphenylboronic acid (5.3 mmol) under the atmosphere of argon. The microwave reactor vial was caped and placed into the microwave cavity. The reaction mixture was irradiated at high level for 30 min at 120 °C. The reaction mixture was cooled to room temperature, pourd onto 100 mL ice-water and then extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with water (2 × 100 mL), brine (100 mL) and dried over anhydrous magnesium sulfate. The solvent was removed under vacuum to afford the crude which was purified by flash column chromatography (silica gel, petroleum ether/ethyl acetate 3:1) to yield the desired phenylisatin derivatives.

To a flask (25 mL) which contained the solution of phenylisatin derivatives (0.86 mmol) in dry N,N-dimethylformamide (2 mL). The reaction temperature was maintained at 0 °C followed by addition K~2~CO~3~ (0.35 g, 2.6 mmol). Stirring 5 min, was added 4-methoxybenzylchloride (0.16 g, 1.0 mmol) and the mixture allowed warm to room temperature. The reaction mixture was stirred at room temperature for 6 h. The orange solution was poured water (25 mL) and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 8:1--3:1) afforded the title compounds **3a-3c**.

### 5.3.1. 1-(4-methoxybenzyl)-4-(4-methoxyphenyl)indoline-2,3-dione **(3a)** {#sec5.3.1}

Yield 51%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 3.87 (s, 3H), 4.89 (s, 2H), 6.72 (d, 1H, *J* = 7.6 Hz), 6.88 (d, 2H, *J* = 8.4 Hz), 6.97 (d, 2H, *J* = 8.8 Hz), 7.02 (d, 1H, *J* = 7.6 Hz), 7.29 (d, 2H, *J* = 8.8 Hz), 7.42--7.46 (m, 1H), 7.49 (d, 2H, *J* = 8.0 Hz). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.52, 55.31, 55.34, 108.96, 113.74, 113.83, 113.83, 114.41, 114.41, 125.61, 126.70, 128.33, 128.90, 128.90, 130.40, 130.40, 137.40, 143.22, 151.50, 158.09, 159.44, 160.53, 182.02. ESI-MS: 374.2 \[M+H\]+.

### 5.3.2. 1-(4-methoxybenzyl)-6-(4-methoxyphenyl)indoline-2,3-dione **(3b)** {#sec5.3.2}

Yield 46%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.78 (s, 3H), 3.86 (s, 3H), 4.91 (s, 2H), 6.88 (d, 2H, *J* = 8.4 Hz), 6.94 (s, 1H), 6.98 (d, 2H, *J* = 8.8 Hz), 7.24 (d, 1H, *J* = 8.0 Hz), 7.30 (d, 2H, *J* = 8.8 Hz), 7.45 (d, 2H, *J* = 8.4 Hz), 7.63 (d, 1H, *J* = 8.0 Hz). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.52, 55.31, 55.45, 108.87, 114.45, 114.45, 114.60, 114.60, 115.96, 121.92, 125.86, 126.71, 128.50, 128.50, 128.93, 128.93, 131.79, 151.12, 151.47, 158.95, 159.46, 160.77, 182.52. ESI-MS: 374.2 \[M+H\]+, 396.2 \[M+Na\]+.

### 5.3.3. 1-(4-methoxybenzyl)-7-(4-methoxyphenyl)indoline-2,3-dione **(3c)** {#sec5.3.3}

Yield 32%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.73 (s, 3H), 3.86 (s, 3H), 4.65 (s, 2H), 6.52 (d, 2H, *J* = 8.4 Hz), 6.63 (d, 2H, *J* = 8.4 Hz), 6.82 (d, 2H, *J* = 8.4 Hz), 6.99 (d, 2H, *J* = 8.4 Hz), 7.07--7.11 (m, 1H), 7.27--7.30 (m, 1H), 7.63 (d, 1H, *J* = 8.4 Hz). ^13^C NMR (100 MHz, CDCl~3~) *δ* 44.71, 55.25, 55.44, 113.49, 113.49, 113.65, 113.65, 119.30, 123.54, 124.42, 126.99, 127.58, 127.58, 127.76, 129.23, 130.72, 130.72, 142.20, 147.24, 158.87, 159.61, 159.99, 183.62. ESI-MS: 374.1 \[M+H\]+, 396.1 \[M+Na\]+.

5.4. Synthesis of compounds **4a-4r** {#sec5.4}
-------------------------------------

To a flask (25 mL) which contained the solution of 5-bromoindoline-2,3-dione (1 g, 4.4 mmol) in dry N,N-dimethylformamide (4 mL). The reaction temperature was maintained at 0 °C followed by addition K~2~CO~3~ (1.83 g, 13.2 mmol). Stirring 5 min, was added 4-methoxybenzylchloride (0.82 g, 5.3 mmol) and the mixture allowed warm to room temperature. The reaction mixture was stirred at room temperature for 8 h. The orange solution was poured water (25 mL) and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 10:1) afforded the title compounds 5-bromo-1-(4-methoxybenzyl)indoline-2,3-dione.

To a microwave reactor vial (2 mL) which contained the solution of 5-bromo-1-(4-methoxybenzyl)indoline-2,3-dione (0.2 g, 0.6 mmol) in 1,4-dioxane (2 mL) were added PdCl~2~(dppf) (21 mg, 0.03 mmol), CH~3~COOK (82 mg, 0.84 mmol) and substituted benzeneboronic acid (0.72 mmol) under the atmosphere of argon. The microwave reactor vial was caped and placed into the microwave cavity. The reaction mixture was irradiated at high level for 30 min at 120 °C. The reaction mixture was cooled to room temperature, poured onto 30 mL ice-water and then extracted with dichloromethane (3 × 50 mL). The combined organic layers were washed with water (2 × 100 mL), brine (100 mL) and dried over anhydrous magnesium sulfate. The solvent was removed under vacuum to afford the crude which was purified by flash column chromatography (silica gel, petroleum ether/ethyl acetate 3:1) to yield the desired compound **4a-4r**.

### 5.4.1. 1-(4-methoxybenzyl)-5-(3-methoxyphenyl)indoline-2,3-dione **(4a)** {#sec5.4.1}

Yield 47%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 3.85 (s, 3H), 4.90 (s, 2H), 6.86 (d, 2H, *J* = 7.6 Hz), 6.91 (d, 2H, *J* = 8.0 Hz), 6.99 (t, 1H), 7.06 (d, 1H, *J* = 7.6 Hz), 7.30 (d, 2H, *J* = 8.0 Hz), 7.35 (d, 1H, *J* = 7.6 Hz), 7.70 (d, 1H, *J* = 8.0 Hz), 7.82 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.70, 55.32, 55.36, 111.33, 112.31, 113.29, 114.46, 114.46, 118.09, 118.98, 123.90, 126.45, 128.98, 128.98, 130.11, 136.77, 137.22, 140.42, 149.89, 158.35, 159.51, 160.14, 183.50. ESI-MS: 374.1 \[M+H\]+, 396.1 \[M+Na\]+.

### 5.4.2. 1-(4-methoxybenzyl)-5-(2-methoxyphenyl)indoline-2,3-dione **(4b)** {#sec5.4.2}

Yield 43%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 3.80 (s, 3H), 4.89 (s, 2H), 6.83 (d, 1H, *J* = 8.0 Hz), 6.88 (d, 2H, *J* = 8.4 Hz), 6.96--7.03 (m, 2H), 7.22 (d, 1H, *J* = 8.0 Hz), 7.29--7.33 (m, 3H), 7.63 (d, 1H, *J* = 8.0 Hz), 7.80 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.61, 55.32, 55.51, 110.68, 111.22, 114.42, 114.42, 117.49, 121.03, 126.59, 126.64, 128.23, 129.01, 129.01, 129.37, 130.18, 134.52, 139.26, 149.40, 156.26, 158.49, 159.47, 183.56. ESI-MS: 374.2 \[M+H\]+, 396.2 \[M+Na\]+.

### 5.4.3. 5-(3,5-dimethoxyphenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4c)** {#sec5.4.3}

Yield 41%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.81 (s, 3H), 3.85 (s, 6H), 4.92 (s, 2H), 6.48 (t, 1H, *J* = 4.4 Hz), 6.61 (s, 2H), 6.87--6.91 (m, 3H), 7.31 (d, 2H, *J* = 8.4 Hz), 7.71 (d, 1H, *J* = 8.4 Hz), 7.84 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.68, 55.32, 55.48, 55.48, 99.71, 104.83, 104.83, 111.32, 114.45, 114.45, 118.00, 123.84, 126.44, 128.99, 128.99, 136.78, 137.20, 141.02, 149.97, 158.35, 159.50, 161.28, 161.28, 183.50. ESI-MS: 404.2 \[M+H\]+, 426.2 \[M+Na\]+.

### 5.4.4. 5-(3,4-dimethoxyphenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4d)** {#sec5.4.4}

Yield 38%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 3.91 (s, 3H), 3.93 (s, 3H), 4.90 (s, 2H), 6.85 (d, 1H, *J* = 8.0 Hz), 6.88 (d, 2H, *J* = 8.0 Hz), 6.92 (d, 1H, *J* = 8.4 Hz), 6.97 (s, 1H), 7.04 (d, 1H, *J* = 8.0 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.67 (d, 1H, *J* = 8.0 Hz), 7.80 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.67, 55.31, 56.01, 56.01, 109.71, 111.33, 111.60, 114.44, 114.44, 118.08, 118.90, 123.48, 126.47, 128.96, 128.96, 131.86, 136.35, 137.22, 149.08, 149.39, 149.39, 158.35, 159.49, 183.65. ESI-MS: 404.2 \[M+H\]+.

### 5.4.5. 5-(4-(tert-butyl)phenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4e)** {#sec5.4.5}

Yield 34%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 1.35 (s, 9H), 3.79 (s, 3H), 4.90 (s, 2H), 6.86 (d, 1H, *J* = 8.4 Hz), 6.89 (d, 2H, *J* = 8.4 Hz), 7.30 (d, 2H, *J* = 8.4 Hz), 7.41--7.47 (m, 4H), 7.70 (d, 1H, *J* = 8.4 Hz), 7.83 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 31.31, 31.31, 31.31, 34.61, 43.67, 55.31, 111.32, 114.45, 114.45, 118.12, 123.66, 126.04, 126.04, 126.19, 126.19, 126.52, 128.99, 128.99, 136.02, 136.54, 137.23, 149.58, 151.07, 158.38, 159.49, 183.58. ESI-MS: 400.1 \[M+H\]+.

### 5.4.6. 5-(4-fluorophenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4f)** {#sec5.4.6}

Yield 41%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.90 (s, 2H), 6.86--6.90 (m, 3H), 7.10--7.15 (m, 2H), 7.29 (d, 2H, *J* = 8.0 Hz), 7.42--7.46 (m, 2H), 7.64 (d, 1H, *J* = 8.0 Hz), 7.78 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.69, 55.32, 111.41, 114.46, 114.46, 115.92, 116.13, 118.14, 123.69, 126.40, 128.18, 128.26, 128.97, 128.97, 135.16, 136.39, 136.54, 149.76, 158.27, 159.52, 161.47, 183.44. ESI-MS: 362.2 \[M+H\]+, 384.2 \[M+Na\]+.

### 5.4.7. 5-(4-chlorophenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4g)** {#sec5.4.7}

Yield 48%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.90 (s, 2H), 6.87 (d, 1H, *J* = 8.4 Hz), 6.88 (d, 2H, *J* = 8.4 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.40 (m, 4H), 7.66 (d, 1H, *J* = 8.4 Hz), 7.79 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.71, 55.32, 111.46, 114.48, 114.48, 118.18, 123.65, 126.36, 127.79, 127.79, 128.96, 128.96, 129.25, 129.25, 134.09, 136.10, 136.50, 137.43, 149.99, 158.24, 159.54, 183.34. ESI-MS: 378.1 \[M+H\]+, 400.1 \[M+Na\]+.

### 5.4.8. 5-(3-chloro-4-fluorophenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4h)** {#sec5.4.8}

Yield 40%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.90 (s, 2H), 6.88 (d, 1H, *J* = 8.4 Hz), 6.89 (d, 2H, *J* = 8.4 Hz), 7.21 (d, 1H, *J* = 8.4 Hz), 7.28--7.34 (m, 3H), 7.51 (d, 1H, *J* = 8.4 Hz), 7.63 (d, 1H, *J* = 8.4 Hz), 7.76 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.73, 55.32, 111.54, 114.49, 114.49, 117.09, 117.30, 118.17, 123.62, 126.23, 126.30, 128.78, 128.97, 128.97, 135.06, 136.28, 136.49, 150.15, 156.70, 158.17, 159.65, 183.23. ESI-MS: 396.1 \[M+H\]+, 418.1 \[M+Na\]+.

### 5.4.9. 1-(4-methoxybenzyl)-5-(p-tolyl)indoline-2,3-dione **(4i)** {#sec5.4.9}

Yield 46%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 2.38 (s, 3H), 3.79 (s, 3H), 4.89 (s, 2H), 6.85 (d, 1H, *J* = 8.0 Hz), 6.88 (d, 2H, *J* = 8.4 Hz), 7.24 (d, 2H, *J* = 8.0 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.37 (d, 2H, *J* = 8.0 Hz), 7.68 (d, 1H, *J* = 8.4 Hz), 7.81 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 21.10, 43.66, 55.31, 111.30, 114.44, 114.44, 118.12, 123.66, 126.38, 126.38, 126.50, 128.96, 128.96, 129.77, 129.77, 136.08, 136.48, 137.35, 137.83, 149.55, 158.37, 159.49, 183.56. ESI-MS: 358.2 \[M+H\]+.

### 5.4.10. 5-(4-isopropoxyphenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4j)** {#sec5.4.10}

Yield 43%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 1.34 (s, 3H), 1.36 (s, 3H), 3.79 (s, 3H), 4.55--4.61 (m, 1H), 4.89 (s, 2H), 6.83 (d, 1H, *J* = 8.4 Hz), 6.88 (d, 2H, *J* = 8.4 Hz), 6.93 (d, 2H, *J* = 8.8 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.39 (d, 2H, *J* = 8.8 Hz), 7.64 (d, 1H, *J* = 8.4 Hz), 7.78 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 22.04, 22.04, 43.65, 55.31, 70.02, 111.28, 114.44, 114.44, 116.27, 116.27, 118.12, 123.35, 126.54, 127.63, 127.63, 128.96, 128.96, 131.15, 136.15, 137.15, 149.21, 157.92, 158.38, 159.48, 183.62. ESI-MS: 402.2 \[M+H\]+.

### 5.4.11. 1-(4-methoxybenzyl)-5-phenylindoline-2,3-dione **(4k)** {#sec5.4.11}

Yield 45%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.78 (s, 3H), 4.89 (s, 2H), 6.87 (d, 1H, *J* = 8.0 Hz), 6.88 (d, 2H, *J* = 8.0 Hz), 7.30 (d, 2H, *J* = 8.8 Hz), 7.36 (d, 1H, *J* = 8.0 Hz), 7.42 (d, 2H, *J* = 8.0 Hz), 7.45 (d, 2H, *J* = 8.8 Hz), 7.46--7.48 (d, 1H, *J* = 8.0 Hz), 7.71 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.68, 55.32, 111.36, 114.45, 114.45, 118.13, 123.85, 126.47, 126.55, 126.55, 127.90, 128.98, 128.98, 129.08, 129.08, 136.73, 137.37, 138.96, 149.79, 158.35, 159.50, 183.50. ESI-MS: 344.2 \[M+H\]+.

### 5.4.12. 4-(1-(4-methoxybenzyl)-2,3-dioxoindolin-5-yl)benzonitrile **(4l)** {#sec5.4.12}

Yield 29%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.91 (s, 2H), 6.89 (d, 2H, *J* = 8.8 Hz), 6.93 (d, 1H, *J* = 8.4 Hz), 7.29 (d, 2H, *J* = 8.8 Hz), 7.59 (d, 2H, *J* = 8.4 Hz), 7.71 (d, 2H, *J* = 8.4 Hz), 7.73 (d, 1H, *J* = 8.4 Hz), 7.84 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.77, 55.32, 111.60, 111.70, 114.50, 114.50, 118.27, 118.54, 123.88, 126.16, 127.13, 127.13, 128.98, 128.98, 132.89, 132.89, 135.10, 136.77, 143.34, 150.76, 158.11, 159.58, 183.06. ESI-MS: 369.2 \[M+H\]+.

### 5.4.13. 1-(4-methoxybenzyl)-5-(4-(trifluoromethyl)phenyl)indoline-2,3-dione **(4m)** {#sec5.4.13}

Yield 31%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.81 (s, 3H), 4.94 (s, 2H), 6.91 (d, 2H, *J* = 8.8 Hz), 6.94 (d, 1H, *J* = 8.0 Hz), 7.32 (d, 2H, *J* = 8.8 Hz), 7.61 (d, 2H, *J* = 8.0 Hz), 7.72 (d, 2H, *J* = 8.8 Hz), 7.74 (d, 1H, *J* = 8.4 Hz), 7.86 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.76, 55.32, 111.57, 114.51, 114.51, 118.24, 123.92, 126.04, 126.08, 126.28, 126.85, 126.85, 128.98, 128.98, 129.84, 130.16, 135.74, 136.80, 142.46, 150.47, 158.19, 159.58, 183.20. ESI-MS: 412.1 \[M+H\]+, 434.1 \[M+Na\]+.

### 5.4.14. 1-(4-methoxybenzyl)-5-(4-(trifluoromethoxy)phenyl)indoline-2,3-dione **(4n)** {#sec5.4.14}

Yield 39%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.90 (s, 2H), 6.87--6.90 (m, 3H), 7.28--7.30 (m, 4H), 7.49 (d, 2H, *J* = 8.8 Hz), 7.66 (d, 1H, *J* = 8.0 Hz), 7.80 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.72, 55.31, 111.48, 114.48, 114.48, 118.19, 121.15, 121.15, 123.75, 126.35, 127.96, 127.96, 128.97, 128.97, 135.91, 136.62, 136.62, 137.71, 149.03, 150.08, 158.23, 159.55, 183.31. ESI-MS: 428.1 \[M+H\]+, 450.0 \[M+Na\]+.

### 5.4.15. 5-(4-hydroxyphenyl)-1-(4-methoxybenzyl)indoline-2,3-dione **(4o)** {#sec5.4.15}

Yield 28%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.89 (s, 2H), 6.84 (d, 1H, *J* = 8.4 Hz), 6.87--6.90 (m, 4H), 7.29 (d, 2H, *J* = 8.4 Hz), 7.36 (d, 2H, *J* = 8.4 Hz), 7.63 (d, 1H, *J* = 8.4 Hz), 7.77 (s, 1H). ^13^C NMR (100 MHz, DMSO) *δ* 42.91, 55.53, 112.03, 114.53, 114.53, 116.23, 116.23, 118.68, 121.99, 127.80, 127.92, 127.92, 129.33, 129.33, 129.76, 135.61, 136.16, 149.16, 157.73, 158.84, 159.18, 183.78. ESI-MS: 360.1 \[M+H\]+, 382.1 \[M+Na\]+.

### 5.4.16. 1-(4-methoxybenzyl)-5-(naphthalen-2-yl)indoline-2,3-dione **(4p)** {#sec5.4.16}

Yield 47%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.92 (s, 2H), 6.89 (d, 2H, *J* = 8.8 Hz), 6.91 (d, 1H, *J* = 8.4 Hz), 7.31 (d, 2H, *J* = 8.8 Hz), 7.49--7.53 (m, 2H), 7.61 (d, 1H, *J* = 8.4 Hz), 7.82--7.89 (m, 6H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.71, 55.32, 111.44, 114.48, 114.48, 118.24, 124.06, 124.57, 125.41, 126.39, 126.47, 126.68, 127.69, 128.16, 128.88, 128.98, 128.98, 132.76, 133.56, 136.22, 136.90, 137.26, 149.82, 158.35, 159.54, 183.49. ESI-MS: 394.1 \[M+H\]+, 416.1 \[M+Na\]+.

### 5.4.17. 1-(4-methoxybenzyl)-5-(pyridin-4-yl)indoline-2,3-dione **(4q)** {#sec5.4.17}

Yield 25%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.92 (s, 2H), 6.89 (d, 2H, *J* = 8.4 Hz), 6.94 (d, 1H, *J* = 8.4 Hz), 7.27 (d, 2H, *J* = 8.4 Hz), 7.45 (d, 2H, *J* = 6.0 Hz), 7.78 (d, 1H, *J* = 8.4 Hz), 7.90 (s, 1H), 8.68 (d, 2H, *J* = 6.0 Hz). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.79, 55.33, 111.73, 114.51, 114.51, 118.30, 120.92, 123.73, 126.15, 128.98, 128.98, 133.99, 136.63, 136.63, 146.25, 150.40, 150.40, 151.14, 158.12, 159.59, 183.01. ESI-MS: 345.2 \[M+H\]+, 367.2 \[M+Na\]+.

### 5.4.18. 1-(4-methoxybenzyl)-5-(thiophen-3-yl)indoline-2,3-dione **(4r)** {#sec5.4.18}

Yield 40%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.79 (s, 3H), 4.89 (s, 2H), 6.83 (d, 1H, *J* = 8.0 Hz), 6.88 (d, 2H, *J* = 8.8 Hz), 7.27--7.30 (m, 3H), 7.37--7.41 (m, 2H), 7.71 (d, 1H, *J* = 8.0 Hz), 7.82 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.69, 55.32, 111.38, 114.45, 114.45, 118.07, 120.52, 123.09, 125.68, 126.43, 127.01, 128.96, 128.96, 132.15, 135.87, 140.08, 149.43, 158.30, 159.50, 183.52. ESI-MS: 350.1 \[M+H\]+, 372.0 \[M+Na\]+.

5.5. Synthesis of compounds **5a-5k** {#sec5.5}
-------------------------------------

A mixture of 0.4 mmol compound **2m**, 0.8 mmol sodium borohydride were stirred in 2 mL dichloromethane and 8 mL ethanol at room temperature under an argon atmosphere. The progress of the reaction was monitored by TLC (petroleum ether/ethyl acetate). After the reaction finished, the reaction mixture was poured water (25 mL) and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 3:1) afforded the title compound **5a**.

A mixture of 0.4 mmol compound **2m**, 0.8 mmol methyl-magnesiubromide (1.0M solution in THF) were stirred in 2 mL dry THF at −78 °C under a argon atmosphere. The progress of the reaction was monitored by TLC (petroleum ether/ethyl acetate). After the reaction finished, the reaction mixture was poured ice water and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 3:1) afforded the title compound **5b**.

A mixture of 0.4 mmol compounds **2m**, 1.2 mmol Hydrazine hydrate were stirred in 5 mL ethanol at reflux under a argon atmosphere. The progress of the reaction was monitored by TLC (petroleum ether/ethyl acetate). After the reaction finished, the reaction mixture was poured water (25 mL) and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 6:1) afforded the title compounds **5c**.

To a flask (25 mL) which contained the solution of compound **2m** (0.15 g, 0.4 mmol) in dry THF (8 mL). The reaction temperature was maintained at 0 °C followed by the added triethyl phosphonoacetate (0.48 mmol) and the mixture allowed warm to room temperature. The reaction mixture was stirred at room temperature for 1 h. The orange solution was poured water (25 mL) and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 8:1) afforded the title compounds **5d** and **5e**.

A mixture of 0.4 mmol compounds **2m**, 1.6 mmol ethylene glycol and 0.06 mmol toluene-*p*-sulfonic acid were stirred in 15 mL toluene at 125 °C under a argon atmosphere. The progress of the reaction was monitored by TLC (petroleum ether/ethyl acetate). After the reaction finished, the reaction mixture was poured water (25 mL) and extracted with ethyl acetate (3 × 40 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 10:1) afforded the title compounds **5f**.

To a flask (25 mL) which contained the solution of compound **2m** (0.15 g, 0.44 mmol) in dry dichloromethane (8 mL). The reaction temperature was maintained at 0 °C followed by the added DAST (77 mg, 0.48 mmol) and the mixture allowed warm to room temperature. The reaction mixture was stirred at room temperature for 2 h. The orange solution was poured water (25 mL) and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 5:1) afforded the title compounds **5g**.

A mixture of 0.4 mmol compounds **2m**, 0.44 mmol hydroxylamine hydrochloride and 0.2 mmol Na~2~CO~3~ were stirred in 10 mL ethanol at reflux under an argon atmosphere. The progress of the reaction was monitored by TLC (petroleum ether/ethyl acetate). After the reaction finished, the reaction mixture was filtered. The filtrate was concentrated to dryness and subjected to flash column chromatography (silica gel), eluting with petroleum ether/ethyl acetate, afforded compounds **5h**.

To a flask (25 mL) which contained the solution of compound **5c** (0.15 g, 0.42 mmol) in ethanol (8 mL) were added Piperidine (4 mg, 0.04 mmol) and substituted benzaldehyde (0.5 mmol) under the atmosphere of argon. The reaction mixture was stirred at reflux for 4 h. The orange solution was poured water (25 mL) and extracted with dichloromethane (3 × 50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and evaporated. Chromatography (petroleum ether/ethyl acetate 10:1--3:1) afforded the title compounds **5i-5k**.

### 5.5.1. 3-hydroxy-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)indolin-2-one **(5a)** {#sec5.5.1}

Yield 59%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.76 (s, 3H), 3.83 (s, 3H), 4.77--4.90 (m, 2H), 5.20 (s, 1H), 6.78 (d, 1H, *J* = 8.4 Hz), 6.85 (d, 2H, *J* = 8.4 Hz), 6.94 (d, 2H, *J* = 8.8 Hz), 7.26 (d, 2H, *J* = 8.4 Hz), 7.39 (d, 1H, *J* = 8.4 Hz), 7.44 (d, 2H, *J* = 8.8 Hz), 7.65 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.48, 55.27, 55.35, 70.01, 109.74, 114.26, 114.26, 114.28, 114.28, 123.78, 127.36, 127.50, 127.81, 127.95, 127.95, 128.79, 128.79, 133.12, 136.38, 141.79, 159.05, 159.22, 176.97. ESI-MS: 376.2 \[M+H\]+.

### 5.5.2. 3-hydroxy-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)-3-methylindolin-2-one **(5b)** {#sec5.5.2}

Yield 59%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 1.68 (s, 3H), 3.77 (s, 3H), 3.83 (s, 3H), 4.77--4.93 (m, 2H), 6.78 (d, 1H, *J* = 8.4 Hz), 6.85 (d, 2H, *J* = 8.4 Hz), 6.94 (d, 2H, *J* = 8.8 Hz), 7.24 (d, 2H, *J* = 8.4 Hz), 7.37 (d, 1H, *J* = 8.4 Hz), 7.44 (d, 2H, *J* = 8.8 Hz), 7.59 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 25.14, 43.32, 55.26, 55.35, 73.87, 109.83, 114.26, 114.26, 114.26, 114.26, 122.09, 127.51, 127.78, 127.82, 127.82, 128.64, 128.64, 131.92, 133.19, 136.40, 140.71, 159.02, 159.16, 178.56. ESI-MS: 390.1 \[M+H\]+, 412.1 \[M+Na\]+.

### 5.5.3. 1-(4-methoxybenzyl)-5-(4-methoxyphenyl)indolin-2-one **(5c)** {#sec5.5.3}

Yield 54%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.65 (s, 2H), 3.77 (s, 3H), 3.83 (s, 3H), 4.87 (s, 2H), 6.78 (d, 1H, *J* = 8.4 Hz), 6.85 (d, 2H, *J* = 8.4 Hz), 6.94 (d, 2H, *J* = 8.8 Hz), 7.27 (d, 2H, *J* = 8.4 Hz), 7.33 (d, 1H, *J* = 8.4 Hz), 7.42 (d, 2H, *J* = 8.8 Hz), 7.43 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 35.93, 43.33, 55.27, 55.35, 109.22, 114.18, 114.18, 114.26, 114.26, 123.04, 125.08, 126.20, 127.80, 127.80, 127.99, 128.80, 128.80, 133.50, 133.55, 143.22, 158.93, 159.11, 175.06. ESI-MS: 360.2 \[M+H\]+, 382.2 \[M+Na\]+.

### 5.5.4. (Z)-ethyl 2-(1-(4-methoxybenzyl)-5-(4-methoxyphenyl)-2-oxoindolin-3-ylidene)acetate **(5d)** {#sec5.5.4}

Yield 76%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 1.35--1.39 (m, 3H), 3.77 (s, 3H), 3.84 (s, 3H), 4.31--4.37 (m, 2H), 4.90 (s, 2H), 6.75 (d, 1H, *J* = 8.0 Hz), 6.85 (d, 2H, *J* = 8.8 Hz), 6.96 (d, 2H, *J* = 8.4 Hz), 7.01 (s, 1H), 7.25 (d, 2H, *J* = 8.4 Hz), 7.44 (d, 1H, *J* = 8.0 Hz), 7.48 (d, 2H, *J* = 8.8 Hz), 8.81 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 14.24, 43.45, 55.28, 55.36, 61.26, 109.34, 114.25, 114.25, 114.28, 114.28, 120.49, 123.00, 127.27, 127.50, 127.81, 127.81, 128.70, 128.70, 130.53, 133.18, 135.88, 137.86, 143.89, 159.02, 159.20, 165.63, 167.73. ESI-MS: 466.3 \[M+Na\]+.

### 5.5.5. (Z)-methyl 2-(1-(4-methoxybenzyl)-5-(4-methoxyphenyl)-2-oxoindolin-3-ylidene)acetate **(5e)** {#sec5.5.5}

Yield 68%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.77 (s, 3H), 3.84 (s, 3H), 3.88 (s, 3H), 4.89 (s, 2H), 6.75 (d, 1H, *J* = 8.0 Hz), 6.85 (d, 2H, *J* = 8.8 Hz), 6.96 (d, 2H, *J* = 8.8 Hz), 7.00 (s, 1H), 7.25 (d, 2H, *J* = 8.8 Hz), 7.44 (d, 1H, *J* = 8.0 Hz), 7.49 (d, 2H, *J* = 8.8 Hz), 8.82 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.74, 52.25, 55.28, 55.37, 109.37, 114.25, 114.25, 114.29, 114.29, 120.45, 122.34, 127.30, 127.47, 127.79, 127.79, 128.71, 128.71, 130.62, 133.13, 135.90, 138.23, 143.94, 159.04, 159.21, 166.07, 167.66. ESI-MS: 430.1 \[M+H\]+, 452.2 \[M+Na\]+.

### 5.5.6. 1\'-(4-methoxybenzyl)-5\'-(4-methoxyphenyl)spiro\[ \[[@bib1],[@bib3]\]dioxolane-2,3′-indolin\]-2′-one **(5f)** {#sec5.5.6}

Yield 89%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.77 (s, 3H), 3.83 (s, 3H), 4.35--4.38 (m, 2H), 4.63--4.66 (m, 2H), 4.78 (s, 2H), 6.72 (d, 1H, *J* = 8.0 Hz), 6.85 (d, 2H, *J* = 8.4 Hz), 6.93 (d, 2H, *J* = 8.8 Hz), 7.24 (d, 2H, *J* = 8.4 Hz), 7.41 (d, 1H, *J* = 8.0 Hz), 7.42 (d, 2H, *J* = 8.8 Hz), 7.55 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.04, 55.27, 55.34, 65.94, 65.94, 102.39, 109.96, 114.22, 114.22, 114.27, 114.27, 123.39, 124.53, 127.28, 127.80, 127.80, 128.64, 128.64, 129.75, 132.99, 136.55, 142.59, 159.06, 159.18, 173.46. ESI-MS: 418.2 \[M+H\]+, 440.2 \[M+Na\]+.

### 5.5.7. 3,3-difluoro-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)indolin-2-one **(5g)** {#sec5.5.7}

Yield 81%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.78 (s, 3H), 3.84 (s, 3H), 4.85 (s, 2H), 6.83 (d, 1H, *J* = 8.4 Hz), 6.87 (d, 2H, *J* = 8.4 Hz), 6.96 (d, 2H, *J* = 8.4 Hz), 7.26 (d, 2H, *J* = 8.4 Hz), 7.42 (d, 2H, *J* = 8.4 Hz), 7.52 (d, 1H, *J* = 8.4 Hz), 7.72 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.61, 55.30, 55.38, 110.83, 114.44, 114.44, 114.44, 114.44, 120.75, 123.10, 123.10, 126.31, 127.83, 127.83, 128.81, 128.81, 131.48, 132.03, 137.27, 141.67, 159.46, 159.48, 165.46. ESI-MS: 396.1 \[M+H\]+, 418.1 \[M+Na\]+.

### 5.5.8. (Z)-3-(hydroxyimino)-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)indolin-2-one **(5h)** {#sec5.5.8}

Yield 87%; ^1^H NMR (400 MHz, DMSO) *δ* 3.71 (s, 3H), 3.78 (s, 3H), 4.90 (s, 2H), 6.90 (d, 2H, *J* = 7.8 Hz), 7.00 (d, 2H, *J* = 7.8 Hz), 7.06 (d, 1H, *J* = 8.0 Hz), 7.30 (d, 2H, *J* = 8.0 Hz), 7.50 (d, 2H, *J* = 8.0 Hz), 7.59 (d, 1H, *J* = 8.0 Hz), 8.20 (s, 1H), 13.63 (s, 1H). ^13^C NMR (100 MHz, DMSO) *δ* 42.56, 55.52, 55.63, 110.51, 114.57, 114.57, 114.88, 114.88, 116.42, 125.15, 127.94, 127.94, 128.57, 129.19, 129.19, 130.26, 132.54, 135.32, 142.01, 143.96, 159.11, 159.19, 163.68. ESI-MS: 389.2 \[M+H\]+.

### 5.5.9. (Z)-3-benzylidene-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)indolin-2-one **(5i)** {#sec5.5.9}

Yield 41%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.78 (s, 3H), 3.81 (s, 3H), 4.96 (s, 2H), 6.79 (d, 1H, *J* = 8.4 Hz), 6.85--6.91 (m, 4H), 7.28--7.35 (m, 5H), 7.43--7.45 (m, 3H), 7.47 (d, 2H, *J* = 8.4 Hz), 7.70 (s, 1H), 7.84 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.35, 55.28, 55.34, 109.37, 114.19, 114.19, 114.26, 114.26, 121.27, 121.82, 127.28, 127.56, 127.56, 128.09, 128.13, 128.65, 128.65, 128.76, 128.76, 129.34, 129.34, 129.73, 133.40, 134.82, 134.99, 137.73, 142.25, 158.88, 159.09, 168.60. ESI-MS: 448.2 \[M+H\]+.

### 5.5.10. (Z)-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)-3-(4-(trifluoromethyl)benzylidene) indolin-2-one **(5j)** {#sec5.5.10}

Yield 39%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 3.77 (s, 3H), 3.85 (s, 3H), 4.93 (s, 2H), 6.80 (d, 1H, *J* = 8.0 Hz), 6.85 (d, 2H, *J* = 8.4 Hz), 6.98 (d, 2H, *J* = 8.4 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.39 (d, 1H, *J* = 8.0 Hz), 7.48 (d, 2H, *J* = 8.4 Hz), 7.63 (s, 1H), 7.69--7.71 (m, 3H), 8.36 (d, 2H, *J* = 8.0 Hz). ^13^C NMR (100 MHz, CDCl~3~) *δ* 43.33, 55.28, 55.36, 109.37, 114.21, 114.21, 114.29, 114.29, 118.01, 121.60, 121.88, 127.28, 127.85, 127.85, 128.04, 128.09, 128.81, 128.81, 128.90, 128.90, 129.65, 129.65, 130.15, 133.50, 134.82, 134.99, 137.75, 142.31, 158.90, 159.06, 168.71. ESI-MS: 516.2 \[M+H\]+.

### 5.5.11. (Z)-3-(4-isopropylbenzylidene)-1-(4-methoxybenzyl)-5-(4-methoxyphenyl)indolin-2-one **(5k)** {#sec5.5.11}

Yield 37%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 1.27 (s, 3H), 1.29 (s, 3H), 2.93--3.00 (m, 1H), 3.76 (s, 3H), 3.85 (s, 3H), 4.95 (s, 2H), 6.78 (d, 1H, *J* = 8.0 Hz), 6.84 (d, 2H, *J* = 8.4 Hz), 6.97 (d, 2H, *J* = 8.4 Hz), 7.29 (d, 2H, *J* = 8.4 Hz), 7.31 (d, 2H, *J* = 8.0 Hz), 7.33 (d, 1H, *J* = 8.0 Hz), 7.49 (d, 2H, *J* = 8.4 Hz), 7.63 (s, 1H), 7.68 (s, 1H), 8.29 (d, 2H, *J* = 8.0 Hz). ^13^C NMR (100 MHz, CDCl~3~) *δ* 23.87, 23.87, 34.20, 43.34, 55.28, 55.35, 109.30, 114.19, 114.19, 114.22, 114.22, 121.29, 122.03, 126.64, 126.75, 126.75, 127.59, 127.59, 127.81, 128.22, 128.78, 128.78, 129.61, 129.61, 132.49, 133.49, 134.69, 138.08, 142.14, 151.07, 158.87, 159.08, 168.75. ESI-MS: 490.2 \[M+H\]+.

5.6. Biology evaluation {#sec5.6}
-----------------------

### 5.6.1. Cell lines and culture conditions {#sec5.6.1}

The human leukemia K562 cell line was purchased from the Shanghai Institutes of Biological Sciences (Shanghai, China). Cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum, 2.05 mM glutamine and 1% penicillin/streptomycin. The medium was replaced once every third days. The umbilical vein endothelial cells (HUVECs) were purchased from ATCC (American type culture collection, USA) and cultured in Ham\'s F-12 medium supplemented with 10% fetal bovine serum, 2.05 mM glutamine and 1% penicillin/streptomycin. The liver cancer cells (HepG2) were grown in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum, 2.05 mM glutamine and 1% penicillin/streptomycin. All cell lines were incubated in a humidified atmosphere of 5% CO2 at 37 °C.

### 5.6.2. Cytotoxic activity assay {#sec5.6.2}

Inhibition of cell proliferation by compound **2m** was measured by the MTT assay. In brief, 100 μl of K562 cells were plated in 96-well plates at a density of 5 × 10^4^ cells/ml for 2 h. Different concentrations of compound **2m** (10--100,000 nM) were added to each well to culture for another 48 h. After 48 h of incubation, 10 μl MTT (5 mg/mL) was added to each well and the plates were further incubated for 4 h. MTT assay was performed using thermo microplate reader. The DMSO-treated controls were calculated as a cell viability value of 100%. The inhibitory concentrations (IC~50~) were obtained by nonlinear regression using GraphPad Prism 4.0. For each experiment, IC~50~ value was calculated from three independent assays.

### 5.6.3. Cell cycle analysis {#sec5.6.3}

For the DNA content analysis, 5 × 10^4^ cells were cultured for 2 h and treated with compound **2m** (30 nM, 300 nM) for 0, 6, 12, 24 and 48 h respectively. Cells were collected and fixed with 1 mL of 70% ice-cold ethanol at −20 °C overnight. Cells then were washed with PBS, incubated with propidium iodide (PI, 50 μg/mL), RNase A (100 μg/mL) and 0.2% Triton × 100 for 30 min in dark at room temperature and analyzed using a FACS Calibur system (version 2.0, BD) using the CELLQuest program (Becton Dickinson). Results were representatives of at least three independent experiments.

### 5.6.4. Flow cytometric analysis of apoptosis {#sec5.6.4}

Apoptotic cells were assayed by the Annexin-V-FITC Apoptosis Detection Kit (Tianjin Sungene Biotech Co., Ltd.) according to the manufacturer\'s instructions. K562 cells were seeded in six-well plates and treated with DMSO or compound **2m** (30 nM, 300 nM) for 0, 6, 12, 24 and 48 h respectively. After the treatment, cells were harvested, washed twice with ice-cold PBS at 2500 rpm and resuspended in 1 × Binding buffer. Then, the cells were stained with 5 μl of Annexin-V-FITC for 10 min and 5 μl of PI (50 μg/mL) for 10 min at room temperature in dark and analyzed by flow cytometry. The fraction of cell population in different quadrants was analyzed using quadrant statistics.

### 5.6.5. Wound healing assay {#sec5.6.5}

Wound healing assay was performed to determine migration rate and repair ability of HepG2 cells. The HepG2 cells were plated in 6-well plates at a density of 2 × 10^5^ cells/well and cultured in Dulbecco\'s modified Eagle\'s medium. After 24 h incubation, the cultured cells grew against the wall of 6-well plates. Then, the HepG2 cells were scratched with a 10 μl pipette tip to make a straight line on the HepG2 cells. The medium in the well was removed and the well of the HepG2 cells was washed for three times by 1 × PBS. The cells were treated with DMSO or compound **2m** (10 nM, 30 nM, 100 nM) for 0, 6, 12, 24, 36 and 48 h respectively, and incubated at 37 °C and 5% CO2 atmosphere. Images of the HepG2 cells were got by a Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan).

### 5.6.6. Transwell assay {#sec5.6.6}

The transwell assay of HepG2 cells was performed using 24-well culture plates containing polycarbonate filter inserts (EMD Millipore corporation, Germany). The HepG2 cells were suspended in Dulbecco\'s modified Eagle\'s medium without fetal bovine serum and 200 μl (2 × 10^5^ cells/well) were added to the upper compartment of the chamber. 600 μl Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum was added to the lower chamber. After 30 min, the cells were treated with DMSO or compound **2m** (10 nM, 30 nM, 100 nM) for 24 h and incubated in 5% CO2 atmosphere at 37 °C. After 24 h, medium in the chamber was removed and the well of the HepG2 cells was washed for three times by 1 × PBS. Then, use the methanol as fixative and DAPI as stain. HepG2 cells on the upper side of the filter were removed using cotton swabs. The photographs of three horizons were taken in random. The migrated HepG2 cells to the lower side of the filter were counted.

### 5.6.7. Tube forming assay {#sec5.6.7}

The capillary-like network formation of HUVEC cells was investigated with Matrigel-coated 96-well culture plates \[[@bib17]\]. Matrigel (13.9 mg/mL; BD Bioscience, San Jose, CA, USA) was thawed at 4 °C. Fifty microliters of the Matrigel was added to each well of the 24-well culture plates and incubated for 30 min at 37 °C for polymerization. The HUVEC cells (1 × 10^5^ cells/well) were suspended in Ham\'s F-12 medium containing 10% FBS, and were then added to the Matrigel-coated wells. After 40 min incubation at 37 °C in 5% CO2 atmosphere, added DMSO or compound **2m** (10 nM, 30 nM, 100 nM) to the cells. Then, the plates were incubated at 37 °C in 5% CO2 atmosphere. After 12 h incubation, the capillary-like tube formation in each well of the culture plates was photographed by a Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan).

Appendix A. Supplementary data {#appsec1}
==============================

Multimedia component 1Multimedia component 1

Mol Files {#appsec1.1}
---------

The following ZIP file contains the MOL files of the most important compounds referred to in this article.MOL file. ZIP file containing the MOL files of the most important compounds in this article.
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